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Based on the recently reported sequence ofa dopamine D2 receptor cloned from rat brain, we prepared a series ofcDNA 
probes to determine the distribution ofmRNA encoding this receptor. Within the forebrain, D2 receptor mRNA is abun- 
dant in the caudate-putamen, accumbens ucleus and olfactory tubercle. Moderate to low levels of mRNA are observed 
in the medial habenular nucleus, diagonal band, lateral septal nucleus, claustrum, dorsal endopiriform nucleus, and ento- 
rhinal cortex. In the mesencephalon, D2 receptor mRNA is abundant within the substantia nigra, pars compacta, nd 
the ventral tegmental rea. Comparison of the distributions ofthe mRNA and ligand binding indicates that both presy- 
naptic and postsynaptic D2 receptors of the nigrostriatal, mesolimbic and mesocortical pathways are derived from the 
same mRNA. 
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1. INTRODUCTION 
On the basis of functional and pharmacological 
data central dopamine receptors have been divided 
into D1 and D2 subtypes. Dopamine D1 and D2 
receptors timulate and inhibit adenylate cyclase, 
respectively, by coupling to different G-proteins 
[1]. D2 receptors are known to be abundant within 
various forebrain regions innervated by 
dopaminergic neurons projecting from the 
mesencephalon. Three major ascending 
dopaminergic pathways are known. The 
nigrostriatal pathway originates in the dopamine 
cell group A9 of the substantia nigra, pars compac- 
ta, and densely innervates various striatal regions. 
The mesolimbic and mesocortical pathways 
originate in the dopamine cell group A10 of the 
ventral tegmental area and innervate various lim- 
bic and cortical structures [2-6]. D2 receptors have 
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also been shown to be presynaptically ocated on 
dopaminergic neurons where they modulate 
dopamine release [7,8]. 
Abnormalities in central dopaminergic function 
have been implicated in the pathophysiology of 
schizophrenia and Parkinson's disease [9-11]. 
Schizophrenia is treated with antipsychotic drugs 
which block central D2 receptors, and Parkinson's 
disease by drugs which lead to their stimulation 
[12,15]. Prolonged treatment with antipsychotic 
agents is associated with extrapyramidal (motor) 
side effects such as tardive dyskinesia [12], Since 
the motor side effects are believed to be mediated 
by receptors located within the striatum, and since 
antipsychotic activity is believed to be mediated by 
sites within limbic and cortical regions, investiga- 
tion of a potential heterogeneity of D2 receptors 
between these brain regions has become a focus for 
drug development [16-18]. 
For many neurotransmitter receptors, cloning 
efforts have indicated a molecular basis for phar- 
macological heterogeneity. For example, several 
subtypes of muscarinic, serotonergic, and 
adrenergic receptors have now been cloned 
[19-26]. These receptor subtypes are expressed in 
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distinct regions of the brain, and in the case of 
muscarinic receptors, different receptor gene pro- 
ducts are expressed in presynaptic versus 
postsynaptic locations [27-29]. Recently, a cDNA 
sequence for a rat brain D2 receptor was reported 
showing significant sequence homology with 
receptors that mediate signal transduction by 
coupling with G-proteins [30]. We prepared a 
series of oligodeoxynucleotide probes to localize 
mRNA encoding this D2 receptor in order to deter- 
mine if the distribution of the mRNA accounts for 
the presynaptic and postsynaptic, as well as 
regional, localizations of this D2 receptor. 
2. MATERIALS AND METHODS 
2.1. Probes 
Three 48 base oligodeoxynucleotide probes were generated 
complementary to regions of the mRNA which encode the N- 
terminal, C-terminal and the third cytoplasmic loop of the D2 
receptor cloned from rat brain and had sequences which were 
complementary to bases 4-51 (5'-GTT CTG CCT CTC CAG 
ATC GTC ATC GTA CCA GGA CAG GTT CAG TGG 
ATC-3 '), 954-1001 (5 '-CAG GAC CTT GTT CTG CTG CTC 
CAG CTC GTG CAC GCG CTC GAT GAA GCT-3'), and 
1198-1245 (5'-GCA GTG CAA GAT CTT CAT GAA GGC 
CTT GCG GAA CTC GAT GTT GAA GGT-3') of the D2 
receptor cDNA [30]. The probes were synthesized on an Ap- 
plied Biosystems automated DNA synthesizer and they were 
purified by preparative gel electrophoresis. For detection of 
mRNAs the probes were 3'-end labeled using terminal deox- 
ynucleotidyl transferase (Bethesda Research Laboratories) and 
deoxyadenosine triphosphate labeled in the a-position with 35S 
for in situ hybridizations and 32p for Northern blots (35S > 
1000 Ci/mmol, 32p > 3000 Ci/mmol, New England Nuclear). 
Labeled under these conditions, the most common length of the 
oligonucleotide 3'-tails was 10 bases. 
2.2. In situ hybridizations 
Brains were dissected from male Sprague-Dawley rats 
(200-250 g), frozen on powdered ry ice, and stored at - 70°C 
until sectioned. Twelve (12)/~m cryostat sections were collected 
on gelatin coated slides and stored at - 70°C until use. In situ 
hybridizations were performed with a probe concentration f
-9  x 10~dpm/50/zl o fbuf fer  [4 x SSC (0.15M NaCI, 
0.015 M sodium citrate, pH 7.2), 50% formamide, 1 x 
Denhardt's (0.02% ficoll, 0.02% polyvinylpyrrolidone, 0.0207o 
bovine serum albumin), 250/zg/ml sheared single-stranded 
salmon sperm DNA, 100 mM dithiothreitol, and 10% dextran 
sulfate] per brain slice at 37°C for 20-24 h in a humid chamber. 
Slides were washed four times for at least 15 min at 55°C in 
1 × SSC, and twice for at least 30 min at room temperature also 
in 1 x SSC. The slides were dried and exposed to X-ray film for 
three weeks. To obtain higher esolution data, some slides were 
dipped into a one to one mixture of NTB3 emulsion (Kodak) 
and water at 42°C and exposed for three weeks. 
2.3. Northern blots 
Various brain regions were dissected at a gross anatomical 
level from male Spragne-Dawley rats (200-250 g), frozen on 
dry ice and stored at -70°C until used. Total RNA was ex- 
tracted from these tissues as described in [31] and 15/~g of total 
RNA was loaded onto each lane of a formaldehyde containing 
agarose gel and then transferred to Genescreen (New England 
Nuclear). Hybridizations were performed according to [32] with 
-9  × 106 dpm/ml of hybridization buffer. Hybridizations were 
done at 37°C for'20-24 h, and then washed with a similar pro- 
tocol to that of in situ hybridizations in situ using 1 x SSPE 
(0.15 M NaC1, 10 mM sodium phosphate, 1 mM EDTA) in- 
stead. The blot was placed in saran wrap and set against film 
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Fig.1. Northern blot analysis of D2 receptor mRNA extracted 
from various rat brain area~ as indicated. The ribosomal bands 
are indicated by black dots, and the molecular size markers in 
kilobases are shown on the left. 
Fig.2. The distribution of D2 receptor mRNA within rat brain. Regions rich in mRNA are light in the photomicrograph. Panels (A-D) 
are coronal sections, and panel (E) is a horizontal section, cp, caudate-putamen; p,endopiriform nucleus; ac, accumbens nucleus; 
ot, olfactory tubercle; ls, lateral septal nucleus, dorsal; is, lateral septal nucleus, intermediate; db, diagonal band; snc, substantia nigra 
pars compacta (A9); vta, ventral tegmental area (Al0); cl, claustrum; ec, entorhinal cortex; pvn, paraventricular nucleus; cb, 
cerebellum. 
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3. RESULTS 
The specificity of these probes was verified bas- 
ed on two criteria. First, all three probes labeled an 
identical pattern of mRNA on cryostat sections of 
rat forebrain, and when the three probes were 
combined the signals were roughly additive (data 
not shown). Second, as shown in fig. 1, a mixture 
of the three probes label a single -2 .9  kb species of 
mRNA on Northern blots of total RNA extracted 
from various rat brain regions. The size of this 
mRNA species is the same as that reported using a 
long cloned probe derived from the rat cDNA [30]. 
The striatum expresses the largest amount of D2 
receptor mRNA, while less mRNA was detected in 
cerebral cortex, brain stem, and cerebellum, and 
none was detected in peripheral tissues (data not 
shown). 
The distribution of D2 receptor mRNA was 
evaluated using in situ hybridization with the 
oligodeoxynucleotide probes to sections of rat 
forebraln. Regions which are richest in D2 receptor 
mRNA are the caudate-putamen, the accumbens 
nucleus and olfactory tubercle (fig.2). D2 receptor 
message is expressed throughout the entire 
caudate-putamen, and a greater number of cells 
express the mRNA in the lateral, rather than the 
medial aspects of this structure. Within the olfac- 
tory tubercle, the highest concentration of D2 
receptor mRNA is in the Islands of Calleja. Addi- 
tional limbic structures express moderate levels of 
mRNA, including the horizontal imb of the 
diagonal band, and both the dorsal and ~ in- 
termediate aspects of the lateral septal nucleus. 
Amygdaloid nuclei as well as the'medial habenular 
nucleus also express moderate levels of mRNA 
(data not shown). Cortical regions expressing this 
mRNA include the claustrum, dorsal endopiriform 
nucleus, and entorhinal cortex. 
We also evaluated the presence of D2 receptor 
mRNA within dopamine containing cells in the rat 
mesencephalon. As illustrated in fig.2D, E and 
fig.3, a high density of mRNA is observed within 
the substantia nigra, pars compacta, and is widely 
distributed in the ventral tegmental rea. The more 
lateral aspects of the pars compacta show the 
highest degree of expression while little is seen in 
the substantia nigra, pars reticulata. High levels of 
expression are also seen in the paraventricular 
nucleus. In sections which are not shown, a 
moderate level of mRNA is observed in the 
dopamine cell group A8 which is a caudal exten- 
sion of A9 and innervates the ventral striatum [2]. 
With in situ hybridization, expression of mRNA 
can be evaluated at a cellular level. The mRNA 
within the substantia nigra is almost exclusively 
associated with the large pigmented cells (fig.3B), 
cells previously observed to have high concentra- 
tions of tyrosine hydroxylase mRNA, the rate 
limiting enzyme of dopamine biosynthesis [32]. 
The vast majority of D2 receptors within the 
caudate-putamen are synthesized by medium sized 
intrinsic neurons (fig.3A), contrary to earlier 
studies which have suggested that descending cor- 
ticostriatal projections contribute a major portion 
of these receptors [33]. By combining these 
methods with immunocytochemistry it may be 
possible to determine the neurotransmitter 
phenotype of individual forebrain cells which ex- 
press D2 receptors, and thus help clarify how 
dopaminergic systems interrelate with other 
neurotransmitter systems. 
4. DISCUSSION 
The distribution of D2 receptor mRNA 
presented here is in good agreement with both the 
known pattern of dopaminergic innervation of 
these forebrain structures and with the distribution 
of the D2 receptor binding sites in brain as outlined 
by receptor autoradiographic studies [34,35]. The 
dorsal striatum possesses the highest levels of D2 
receptors, and our results verify that this region ex- 
presses the highest levels of D2 receptor mRNA. 
The fact that we observe a medial to lateral gra- 
dient in expression is consistent with the known 
topographical organization of the ascending 
dopaminergic projections [2,3]. Further, we see ex- 
pression of this message in perhaps all of the limbic 
structures that are known to be dopaminergically 
Fig.3. Dark and bright field micrographs of the distribution of D2 receptor mRNA within rat brain. Rat forebrain (A and C) and 
mesencephalon (B and D) are shown. (A) Caudate-putamen, and(B) the substantia nigra, pars compacta, were both counterstained 
with cresyl violet. The arrows indicate xamples ofcells which express the mRNA. Abbreviations u ed are the same as fig.2. The bar 
represents 10/zm in length. 
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innervated. In cortical regions we see significant 
expression in the piriform and entorhinal cortex, 
but little in prefrontal and cingulate cortex. Final- 
ly, since there are no known intrinsic dopamine 
containing neurons within these forebrain struc- 
tures [2,3], and since the mRNA is only present 
within cell bodies and proximal dendrites 
(fig.3A,B), these data indicate that this mRNA en- 
codes receptors which are postsynaptic with 
respect to the nigrostriatal, mesolimbic and 
mesocortical pathways. 
The distribution of D2 receptor mRNA within 
the mesencephalon is consistent with the distribu- 
tion of neuronal cell bodies which give rise to the 
ascending dopaminergic pathways. We have 
shown that the D2 receptor message is expressed 
widely throughout the ventral tegmental area and 
substantia nigra, pars compacta, and not the pars 
reticulata. Coupled with the observation that the 
distribution of this D2 receptor message coincides 
with that of tyrosine hydroxylase mRNA, our 
results suggest that presynaptic D2 receptors of the 
various ascending pathways are encoded by the 
same mRNA as postsynaptic receptors. 
Overall, the distribution of this mRNA is consis- 
tent with the known distribution of both presynap- 
tically and postsynaptically ocated D2 receptors of 
the examined pathways. The widespread istribu- 
tion of this mRNA has important implications 
with regard to the pharmacology of dopamine 
receptors and future prospects for the development 
of dopaminergic drugs which discriminate between 
receptors located in these different brain regions. 
In the case of other G-protein coupled receptors, it
has been shown that when the same receptor genes 
are expressed in different cells, their antagonist 
pharmacology does not vary with respect o cell 
type [25,26,36], while agonist pharmacology varies 
with respect o both cell type and levels of receptor 
([28] and unpublished observations). Initial results 
with the cloned D2 receptors indicate that a similar 
relationship may hold since D2 receptors expressed 
in fibroblasts have the same affinity for an- 
tagonists and a lower affinity for agonists than do 
D2 receptors expressed by brain [30]. 
Thus one may speculate that at least a portion of 
the D2 receptors expressed by both dopamine 
neurons and their various postsynaptic targets are 
likely to have similar antagonist but different 
agonist pharmacologies. This may explain the dif- 
ferences in agonist pharmacology between 
presynaptic and postsynaptic D2 receptors [37,38]. 
In the case of antagonists, the apparent differences 
in pharmacology between brain regions are incon- 
sistent with the above relationships, and are sug- 
gestive of the possible existence of additional 
receptor subtypes. It should be pointed out 
however, that these data could also be explained by 
an interaction with additional receptors, for exam- 
ple, with muscarinic receptors [12]. 
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